QR код

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the tim...

Повний опис

Збережено в:
Автори: Omran Saifi, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, Youssef H. Zeidan, MD, PhD, Jennifer Peterson, MD, William G. Rule, MD, Scott C. Lester, MD, Bradford S. Hoppe, MD, MPH
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2020-06-01
Серія:International Journal of Particle Therapy
Предмети:
car t-cell therapy
proton therapy
bridging therapy
non-hodgkin lymphoma
Онлайн доступ:https://theijpt.org/doi/pdf/10.14338/IJPT-20-00004.1
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси